Jill Wechsler is a veteran reporter specializing in federal health care and pharmaceutical issues.
The Medicare Part D prescription drug program has emerged as the poster child for how private plans can control costs while providing quality care. Even critics of health insurers acknowledge that the drug benefit has been a success.
The Medicare Part D prescription drug program has emerged as the poster child for how private plans can control costs while providing quality care. Even critics of health insurers acknowledge that the drug benefit has been a success.A recent report from the Kaiser Family Foundation (KFF) documents how government outlays for Part D have been about 30% lower than originally projected by the Congressional Budget Office in 2003, during a period when overall Medicare spending has skyrocketed. The savings arise from a number of factors, said analyst Jack Hoadley of Georgetown University at a KFF briefing: lower enrollment in Part D than expected; a general slowdown in total spending on prescription drugs; fewer new drugs; and, most notably, a huge rise in generic utilization.
Karen Ignagni, president of America's Health Insurance Plans (AHIP), credited the savings to the ability of Part D plans to apply a range of tools to drug utilization, including tiered formularies. Even economist Marilyn Moon, an advocate for consumer protection, acknowledged that private plans have been able to use financial incentives to push beneficiaries into generics, which would be hard for the federal government to do.
The prospect of more new, high-priced therapies coming to market, though, has plans and payers anxious about how to provide coverage for potentially life-saving but budget-busting medicines. With $50,000 to $100,000 price tags expected on a new wave of targeted therapies for cancer, rheumatoid arthritis, multiple sclerosis and other critical diseases, payers are looking to limit prescribing to those patients most likely to benefit, based on biomarkers and diagnostic tests. In addition to step therapy, prior authorization and tiered formularies, payers want pharma companies to provide outcomes studies and comparative effectiveness research that document product value.Part D plans have "a very good deal," according to Moon, because the program's "donut hole" structure relieves insurers from covering high-cost patients. The program's reinsurance system, plus subsidies for seniors also on Medicaid, reduce pressure on plans to manage spending on high-cost medicines. The approval of more costly critical therapies, though, could raise overall spend, prompting further changes in benefit design.
MODEL FOR COMPETITION
A broader policy issue is whether the ability of drug plans to offer choice while managing costs provides a model for shifting the entire Medicare program to a "premium support" system, as advocated by Republicans. Instead of the current fee-for-service, government-run health program, conservatives want to provide seniors with a voucher to purchase private coverage.
But market competition might not be responsible for lower Part D spending, according to Hoadley, noting that high initial cost estimates and lower drug trends might be more responsible for savings.
Yet former Health and Human Services Secretary Mike Leavitt, now health advisor to Mitt Romney, regards Part D as a model for a reformed Medicare system. Conservative analyst James Carpetta credits Part D's success on the ability of plans to offer many options, noting that reasonable government oversight of the program, with rules governing plan bidding and basic drug coverage, still provides flexibility for changes over time.